L3VLUP
ProSign in

CTKB · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CTKBLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CTKB
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterCTKBLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 2021none listed holders, n.a.31 holders, $29.9bn
Q4 2021none listed holders, n.a.31 holders, $34.7bn
Q1 20221 holders, $597k24 holders, $35.3bn
Q2 20222 holders, $22m33 holders, $42.7bn
Q3 20221 holders, $463k31 holders, $43.4bn
Q4 20221 holders, $320k31 holders, $46.6bn
Q1 20231 holders, $747k33 holders, $44.3bn
Q2 20231 holders, $987k37 holders, $59.6bn
Q3 2023none listed holders, n.a.44 holders, $67.6bn
Q4 2023none listed holders, n.a.45 holders, $73.6bn
Q1 2024none listed holders, n.a.41 holders, $95.3bn
Q2 2024none listed holders, n.a.43 holders, $110bn
Q3 2024none listed holders, n.a.45 holders, $107bn
Q4 2024none listed holders, n.a.46 holders, $93.9bn
Q1 2025none listed holders, n.a.42 holders, $98.4bn
Q2 2025none listed holders, n.a.43 holders, $93.2bn
Q3 2025none listed holders, n.a.39 holders, $86.7bn
Q4 20251 holders, $464k41 holders, $123bn
Q1 20261 holders, $380k39 holders, $106bn
Q2 20261 holders, $385k44 holders, $132bn
CTKB

Cytek Biosciences Inc

Holders
1
Reported value
$385k
Buyers
19
Sellers
4

Breadth +15 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
44
Reported value
$132bn
Buyers
24
Sellers
24

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only CTKB (1)

PDT Partners LLC

Only LLY (44)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Discovery Capital Management LLC, Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Glenview Capital Management LLC, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, and 19 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →